FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
FDA has expanded Camzyos's approval to treat symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients as young as 12.
News|Articles|July 29, 2026
What FDA's Peptide Decision Means for the Industry
Author(s)Nicholas Jacobus
An FDA advisory panel voted to recommend six of seven unapproved peptides for compounding access, raising concerns about its newly appointed members.
Advertisement
Advertisement
In a two-day meeting that exposed deep fault lines, an FDA advisory committee voted to recommend that compounding pharmacies be allowed to manufacture six of seven unapproved peptides under review.
Related to this article
New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.
FDA this week cleared three new treatments: Lilly's Olumiant for adolescent alopecia areata, AbbVie's Juvmo for Parkinson's disease, and Mirum and Incyte's Atebrioz for the rare bone disorder FOP.
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.
FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma.
FDA approves Onswik, Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes.
Novartis licenses Abogen's mRNA-encoded CD19xCD3 T-cell engager, while AstraZeneca and Daiichi Sankyo partner with Summit Therapeutics.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Advertisement
Advertisement